Sulforaphane modulates the inflammation and delays neurodegeneration on a Retinitis Pigmentosa mice model

dc.centroUniversidad Cardenal Herrera-CEU
dc.contributor.authorCantó Catalá, Antolín
dc.contributor.authorAlmansa Frías, María Inmaculada
dc.contributor.authorHernández Rabaza, Vicente
dc.contributor.authorMartínez González, Javier
dc.contributor.authorMiranda Sanz, María
dc.contributor.authorOlivar Rivas, Teresa
dc.contributor.otherProducción Científica UCH 2022
dc.contributor.otherUCH. Departamento de Ciencias Biomédicas
dc.date2022
dc.date.accessioned2022-11-05T05:00:44Z
dc.date.available2022-11-05T05:00:44Z
dc.date.issued2022-03-01
dc.descriptionEste artículo se encuentra disponible en la página web de la revista en la siguiente URL: https://www.frontiersin.org/articles/10.3389/fphar.2022.811257/full
dc.description.abstractThe term retinitis pigmentosa (RP) describes a large group of hereditary retinopathies. From a cellular view, retinal degeneration is prompted by an initial death of rods, followed later by cone degeneration. This cellular progressive degeneration is translated clinically in tunnel vision, which evolves to complete blindness. The mechanism underlying the photoreceptor degeneration is unknown, but several mechanisms have been pointed out as main co-stars, inflammation being one of the most relevant. Retinal inflammation is characterized by proliferation, migration, and morphological changes in glial cells, in both microglia and Müller cells, as well as the increase in the expression of inflammatory mediators. Retinal inflammation has been reported in several animal models and clinical cases of RP, but the specific role that inflammation plays in the pathology evolution remains uncertain. Sulforaphane (SFN) is an antioxidant natural compound that has shown antiinflammatory properties, including the modulation of glial cells activation. The present work explores the effects of SFN on retinal degeneration and inflammation, analyzing the modulation of glial cells in the RP rd10 mice model. A daily dose of 20 mg/kg of sulforaphane was administered intraperitoneally to control (C57BL/6J wild type) and rd10 (Pde6brd10) mice, from postnatal day 14 to day 20. On postnatal day 21, euthanasia was performed. Histological retina samples were used to assess cellular degeneration, Müller cells, and microglia activation. SFN administration delayed the loss of photoreceptors. It also ameliorated the characteristic reactive gliosis, assessed by retinal GFAP expression. Moreover, sulforaphane treatment regulated the microglia activation state, inducing changes in the microglia morphology, migration, and expression through the retina. In addition, SFN modulated the expression of the interleukins 1β, 4, Ym1, and arginase inflammatory mediators. Surprisingly, M2 polarization marker expression was increased at P21 and was reduced by SFN treatment. To summarize, SFN administration reduced retinal neurodegeneration and modified the inflammatory profile of RP, which may contribute to the SFN neuroprotective effect.
dc.formatapplication/pdf
dc.identifier.citationCanto, A., Martínez-González, J., Miranda, M., Olivar, T., Almansa, I. & Hernández-Rabaza, V. (2022). Sulforaphane modulates the inflammation and delays neurodegeneration on a Retinitis Pigmentosa mice model. Frontiers in Pharmacology, vol. 13, art. 811257 (01 mar.). DOI: https://doi.org/10.3389/fphar.2022.811257
dc.identifier.doihttps://doi.org/10.3389/fphar.2022.811257
dc.identifier.issn1663-9812 (Electrónico)
dc.identifier.urihttp://hdl.handle.net/10637/14021
dc.language.isoen
dc.publisherFrontiers Media
dc.relationEste artículo de investigación ha sido financiado por la Generalitat Valenciana (GV/2019/034), por el Proyecto Precompetitivo de la Fundación San Pablo CEU (FUSP-PPC19-19F1741D) y por los Indicadores de productividad UCH-Universidad CEU (INDI21/39). También, se ha recibido ayuda de las subvenciones ACIF/199/2019 y FPU 20/06277.
dc.relationUCH. Financiación Autonómica
dc.relationUCH. Financiación Universidad
dc.relation.ispartofFrontiers in Pharmacology, vol. 13 (01 mar. 2022)
dc.relation.projectIDGV/2019/034
dc.relation.projectIDFUSP-PPC19-19F1741D
dc.relation.projectIDINDI21/39
dc.relation.projectIDACIF/199/2019
dc.relation.projectIDFPU 20/06277
dc.rightsopen access
dc.rights.cchttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subjectRetinitis pigmentaria - Tratamiento.
dc.subjectSulforaphane - Therapeutic use.
dc.subjectRetinitis pigmentosa - Treatment.
dc.subjectRetina - Diseases - Treatment.
dc.subjectSulforafano - Uso terapéutico.
dc.subjectRetina - Enfermedades - Tratamiento.
dc.titleSulforaphane modulates the inflammation and delays neurodegeneration on a Retinitis Pigmentosa mice model
dc.typeArtículo
dspace.entity.typePublicationes
relation.isAuthorOfPublicatione36a0fd5-6bd6-4eb4-8155-f1dd017135c2
relation.isAuthorOfPublicatione8459f89-0c0f-4f6c-bc14-ba2cc657592d
relation.isAuthorOfPublication2de42857-af48-4a13-9fc1-8bf501149cd0
relation.isAuthorOfPublication9666899a-a9c5-4069-b9d1-adc49bb21317
relation.isAuthorOfPublicationf8d3d1a6-1612-41de-b48e-2c5e6f3c4bec
relation.isAuthorOfPublication9009b127-1051-4902-8421-0bc3666ef6b2
relation.isAuthorOfPublication.latestForDiscoverye36a0fd5-6bd6-4eb4-8155-f1dd017135c2

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Sulforaphane_Canto_FIP_2022.pdf
Size:
7.34 MB
Format:
Adobe Portable Document Format